Ageing is the major demographic change of this millennium, with important implications for disease, disability, handicap and health care practice and policy. By the year 2030, a conservative estimate is that 25% of all elderly will have significant neuropsychiatric syndromes. The major brain disorder of concern is Alzheimer's disease (AD). This project will use -omics technologies and targeted techniques to identify biomarkers of early and pre-clinical stages of AD, and follow them longitudinally. Detection of dementia-related changes in the preclinical stages will ultimately provide a diagnostic tool and allow prevention and targeted early intervention for neurocognitive disorders.
Back to search results